

FluCov Influenza Activity Report #15

4 March 2024


Take home: elevated but decreasing influenza activity in the Northern Hemisphere

- North America and Europe: Although decreasing, influenza activity in the United States remains elevated with moderate to high activity in many states. In Europe, a mixed activity pattern was observed. Influenza activity decreased in many countries (Denmark, France, Germany, Italy, Spain and UK), but activity continues to vary from very low activity in Italy and Spain to high activity in France and Germany.
- Asia: Influenza overall positivity rate continued to decrease in China, but remained elevated, with moderate activity reported overall.
- Circulating virus: While A/H3 and B/Victoria have predominated globally and in China,
 A/H1N1pdm09 has dominated circulation in most of the Northern Hemisphere. Presently, there are no documented cases of B-Yamagata.
- Vaccine match: US (CDC) reports that vaccine components are well-matched to circulating A(H1N1)pdm09, B/Victoria and A(H3) clades. The same is true for Europe (ECDC) with the exception that some A(H3) viruses (2a.3a.1 clade) are less well-matched (ERVISS).
- Influenza Viruses of Pandemic Potential: No IVPP events of note reported this week.
- COVID hospitalizations: Continue to decrease in England, EU and the US, after a peak around the end of 2023.

Positive Influenza tests (%)


Note: the positivity rate graph for Denmark was last updated week 06/2024, graphs for France, Germany, Italy and the UK were last updated week 07/2024

—— Season 2023/2024 —— Season 2022/2023 —— Season 2021/2022 —— Average of pre-COVID-19 seasons (2014/2015 to 2018/2019) [Min; Max]



Weekly COVID-19 hospital admissions

(England, EU/EEA, US - admissions/100,0000)



Displayed data is the most recent reported; it is possible that there may be a delay in reporting. Most recent estimates subject to change (e.g. may decline) due to ongoing testing of specimen.

Data sources & details

China: China CDC

US: FluView (Clinical Laboratories)

DK: WHO FluNET (non-sentinel)

All others: WHO FluNet (sentinel)

COVID: US (Department of Health and Human Services) EU (ERVISS), England (UKHSA)

Vaccine match: US (CDC), EU (ERVISS)

A Nivel publication

FluCov team: Susanne Heemskerk, Bronke Boudewijns, Marco Del Riccio, Saverio Caini, John Paget. FluCov Influenza Activity Report #15: 4 March 2024. Netherlands, Utrecht: Nivel, 2024

Websites for more information

Project Website: https://www.nivel.nl/en/flucov

FluCoV Dashboard: https://www.nivel.nl/en/flucov-dashboard

Funding

The Nivel FluCov project is funded by Sanofi

Nivel 2